[1]刘海龙,张维华,吴晓康.肠道菌群在2型糖尿病发病作用中的研究进展[J].现代检验医学杂志,2017,32(04):157-159,164.[doi:10.3969/j.issn.1671-7414.2017.04.045]
　LIU Hai-long,ZHANG Wei-hua,WU Xiao-kang.Research Progress on the Function of Intestinal Flora in Type 2 Diabetes Mellitus[J].Journal of Modern Laboratory Medicine,2017,32(04):157-159,164.[doi:10.3969/j.issn.1671-7414.2017.04.045]
点击复制

肠道菌群在2型糖尿病发病作用中的研究进展()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年04期
页码:
157-159,164
栏目:
综述
出版日期:
2017-07-25

文章信息/Info

Title:
Research Progress on the Function of Intestinal Flora in Type 2 Diabetes Mellitus
文章编号:
1671-7414(2017)04-157-04
作者:
刘海龙1; 张维华2; 吴晓康1
1.西安交通大学第二附属医院检验科,西安 710004; 2.陕西省人民医院血液科,西安 710068
Author(s):
LIU Hai-long1; ZHANG Wei-hua2; WU Xiao-kang1
1.Department of Clinical Laboratory, the Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710004,China; 2.Department of Hematology,Shaanxi Provincial People's Hospital,Xi'an710068,China
关键词:
肠道菌群;  2型糖尿病
分类号:
R587.1; R446
DOI:
10.3969/j.issn.1671-7414.2017.04.045
文献标志码:
A
摘要:
2型糖尿病(type 2 diabetes mellitus,T2DM)是一种多病因引起的以高血糖为特征的代谢紊乱疾病,近几十年以来全球范围发病率显著升高,对其预防和治疗也越来越受到关注。肠道菌群是近年来研究的热点之一,大量研究表明肠道菌群与T2DM的发生及其治疗有着密切关系,肠道菌群有望成为改善和治疗T2DM的新方向。该文就近年来T2DM与肠道菌群的相关性、发病机制及治疗研究做一综述。
Abstract:
Type 2 diabetes mellitus is a metabolic disordercharacterized by hyperglycemia caused by multifactors.The incidence of type 2diabetes is gradually increased.Its prevention and treatment are paid more andmore attention.Intestinal flora is one of the hot spots in recent years.A large number of studies have shown that intestinal flora is closely related to the occurrence and treatment of type 2 diabetes mellitus.Intestinal flora is expected to be a new direction for the improvement and treatment of type 2 diabetes mellitus.In this paper,the relationship between type 2 diabetes and intestinal microflora in recent years,pathogenesis and treatment were summarized.

参考文献/References:

[1] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中国糖尿病杂志,2014,22(8):2-42. Chinese Diabetes Society.Guidelines for the prevention and treatment of type 2 diabetes in China(2013Edition)[J].Chinese Journal of Diabetes,2014,22(8):2-42.
[2] Million M,Lagier JC,Yahav D,et al.Gut bacterial mi-crobiota and obesity[J].Clinical Microbiology and Infection.2013,19(4):305-313.
[3] Karlsson F,Tremaroli V,Nielsen J,et al.Assessing the human gut microbiota in metabolic diseases[J]Diabetes,2013,62(10):3341-3349.
[4] Qin J,Li Y,Cai Z,et al.A metagenome-wide association study of gut microbiota in type 2 diabetes[J].Nature,2012,490(7418):55-60.
[5] Larsen N,Vogensen FK,van den Berg FW,et al.Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults[J].PLoS One,2010,5(2):e9085.
[6] Sato J,Kanazawa A,Ikeda F,et al.Gut dysbiosis and detection of “livegut bacteria” in blood of Japanese patients with type 2 diabetes[J].Diabetes Care,2014,37(8):2343-2350.
[7] Dao MC, Everard A, Aron-Wisnewsky J,et al.Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity:relationship with gut microbiome richness and ecology[J].Gut,2016,65(3):426-436.
[8] Fei N,Zhao L.An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice[J].ISME J.2013,7(4):880-884.
[9] Cani PD,Osto M,Geurts L,et al.Involvement of gut microbiotain the development of low-grade inflammation and type 2 diabetes associated with obesity[J].Gut Microbes,2012,3(4):279-288.
[10] Cani PD,Amar J,Iglesias MA,et al.Metabolic endotoxemia initiates obesity and insulin resistance[J].Diabetes,2007,56(7):1761-1772.
[11] Everard A,Cani PD.Gut microbiota and GLP-1[J].Rev Endocr Metab Disord,2014,15(3):189-196.
[12] Drucker DJ.The cardiovascular biology of glucagon-like peptide-1[J].Cell Metab,2016,24(1):15-30.
[13] de la Cuesta-Zuluaga J,Mueller NT,Corrales-Agu-delo V,et al.Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut[J].Diabetes Care,2017,40(1):54-62.
[14] Perino A,Pols TW,Nomura M,et al.TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation[J].J Clin Invest,2014,124(12):5424-5436.
[15] Fang S,Suh JM,Reilly SM,et al.Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance[J].Nat Med,2015,21(2):159-165.
[16] Yun SI,Park HO,Kang JH.Effect of lactobacillus gasseri BNR17 on bloodglucose levels and body weight in a mouse model of type 2 diabetes[J].J ApplMicrobiol,2009,107(5):1681-1686.
[17] Tonucci LB,Olbrich Dos Santos KM,Licursi de Oliveira L,et al.Clinical application of probiotics in type 2 diabetes mellitus:A randomized,double-blind,placebo-controlled study[J].Clin Nutr,2017,36(1):85-92.
[18] Su B,Liu H,Li J,et al.Acarbose treatment affects the serum levels ofinflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus[J].J Diabetes,2015,7(5):729-739.
[19] Zhang X,Fang Z,Zhang C,et al.Effects of acarbose on the gut microbiota of prediabetic patients:a randomized,double-blind,controlled crossover trial[J].Diabetes Ther,2017,8(2):293-307.
[20] Xu J,Lian F,Zhao L,et al.Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula[J].ISME J,2015,9(3):552-562.
[21] Zhang X,Zhao Y,Zhang M,et al.Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats[J].PLoS One,2012,7(8):e42529.
[22] Wang Y,Shou JW,Li XY,et al.Berberine-induced bioactive metabolitesof the gut microbiota improve energy metabolism[J].Metabolism,2017(70):72-84.
[23] Ridaura VK,Faith JJ,Rey FE,et al.Cultured gut microbiota from twinsdiscordant for obesity modulate adiposity and metabolic phenotypes in mice[J].Science,2013,341(6150):1241214.
[24] Hartstra AV,Bouter KE,B(¨overa)ckhed F,et al.Insights into the role of the microbiome in obesity and type 2 diabetes[J].Diabetes Care,2015,38(1):159-165.
[25] Woodworth MH,Carpentieri C,Sitchenko KL,et al.Challenges in fecal donor selection and screening for fecal microbiota transplantation:A review[J].Gut Microbes,2017,8(3):225-237.

相似文献/References:

[1]余安运,刘夏炎,宋 煜,等.血清脂蛋白(a)和同型半胱氨酸(HCY) 与2型糖尿病胰岛素抵抗的临床研究[J].现代检验医学杂志,2016,31(03):65.[doi:10.3969/j.issn.1671-7414.2016.03.018]
　YU An-yun,LIU Xia-yan,SONG Yu,et al.Clinical Study of Serum Lipoprotein(a) and Homocysteine with Type 2 Diabetes Mellitus and Insulin Resistance[J].Journal of Modern Laboratory Medicine,2016,31(04):65.[doi:10.3969/j.issn.1671-7414.2016.03.018]
[2]李 礼,胡娟玉,于正清.IL-19在2型糖尿病患者中的 表达及与血管病变的关系[J].现代检验医学杂志,2016,31(03):92.[doi:10.3969/j.issn.1671-7414.2016.03.025]
　LI Li,HU Juan-yu,YU Zheng-qing.Expression of Interleukin-19 and Its Relationship with Angiopathy in 2 Diabetes Mellitus[J].Journal of Modern Laboratory Medicine,2016,31(04):92.[doi:10.3969/j.issn.1671-7414.2016.03.025]
[3]王继贵.基质金属蛋白酶和代谢综合征的研究进展[J].现代检验医学杂志,2015,30(03):1.[doi:10.3969/j.issn.1671-7414.2015.03.001]
　WANG Ji-gui.Progress of Research on Matrix Metalloproteinases and Metabolic Syndrome[J].Journal of Modern Laboratory Medicine,2015,30(04):1.[doi:10.3969/j.issn.1671-7414.2015.03.001]
[4]张月芳a,马芳莲,朱亚宁b,等.儿童抗幽门螺旋杆菌感染治疗对肠道菌群影响的研究[J].现代检验医学杂志,2015,30(05):32.[doi:10.3969/j.issn.1671-7414.2015.05.010]
　ZHANG Yue-fanga,MA Fang-lian,ZHU Ya-ningb,et al.Research on the Effects of Anti Helicobacter Pylori Infection on Intestinal Flora of Children[J].Journal of Modern Laboratory Medicine,2015,30(04):32.[doi:10.3969/j.issn.1671-7414.2015.05.010]
[5]李国春a,曹 娜a,王 忆b,等.基础血尿酸水平与糖负荷后胰岛素分泌相关性研究[J].现代检验医学杂志,2015,30(02):105.[doi:10.3969/j.issn.1671-7414.2015.02.032]
　LI Guo-chuna,CAO Naa,WANG Yib,et al.Relationship between Concentration of Fasting Uric Acid and Insulin Secretion after Glycemia Burden[J].Journal of Modern Laboratory Medicine,2015,30(04):105.[doi:10.3969/j.issn.1671-7414.2015.02.032]
[6]李晓燕,李晓华,王养维.幽门螺杆菌感染与2型糖尿病发病机制的相关性探讨[J].现代检验医学杂志,2017,32(01):1.[doi:10.3969/j.issn.1671-7414.2017.01.001]
　LI Xiao-yan,LI Xiao-hua,WANG Yang-wei.Helicobacter Pylori Infection and the Pathogeenesis of Type 2Diabetes[J].Journal of Modern Laboratory Medicine,2017,32(04):1.[doi:10.3969/j.issn.1671-7414.2017.01.001]
[7]刘彦君a,梁君蓉b,庞晓宁a.血清趋化素及hs-CRP水平对2型糖尿病患者无症状亚临床动脉粥样硬化诊断的临床意义[J].现代检验医学杂志,2017,32(02):36.[doi:10.3969/j.issn.1671-7414.2017.02.010]
　LIU Yan-juna,LIANG Jun-rongb,PANG Xiao-ninga.Clinical Significance of Serum Chemerin and hs-CRP in the Diagnosis of Subclinical Atherosclerosis in Patients with Type 2 Diabetes[J].Journal of Modern Laboratory Medicine,2017,32(04):36.[doi:10.3969/j.issn.1671-7414.2017.02.010]
[8]李 薪,魏力强.2型糖尿病患者血清中脂蛋白相关磷脂酶A2检测的临床意义[J].现代检验医学杂志,2017,32(06):85.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　LI Xin,WEI Li-qiang.Clinical Significance of Detection of Lipoprotein Associated Phospholipase A2 in Serum of Patients with Type 2 Diabetes Mellitus[J].Journal of Modern Laboratory Medicine,2017,32(04):85.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[9]张 梅,李林娟,冯旭霞a,等.T2DM并发NAFLD患者血清Nesfatin-1水平变化及相关影响研究[J].现代检验医学杂志,2018,33(01):77.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　ZHANG Mei,LI Lin-juan,FENG Xu-xiaa,et al.Analysis of T2DM to the Serum Nesfatin-1 Level Changes of Patients with NAFLD Horizontal[J].Journal of Modern Laboratory Medicine,2018,33(04):77.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[10]张阳东,周建荣,楚瑞雪,等.PECAM-1基因rs7503550位点多态性和表达水平与冠心病及2型糖尿病的相关性研究[J].现代检验医学杂志,2019,34(03):21.[doi:10.3969/j.issn.1671-7414.2019.03.005]
　ZHANG Yang-dong,ZHOU Jian-rong,CHU Rui-xue,et al.Relativity Study on rs7503550 Polymorphism and Genes Expression Levelsof PECAM-1 in Coronary Artery Disease and Type 2 Diabetes Mellitus[J].Journal of Modern Laboratory Medicine,2019,34(04):21.[doi:10.3969/j.issn.1671-7414.2019.03.005]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81200583); 中央高校基本科研业务费专项资金资助(xjj2015151)。 作者简介:刘海龙(1989-),男,在读硕士研究生,主要从事肠道菌群与代谢性疾病相关性研究,E-mail:lhl407138@126.com。 通讯作者:吴晓康(1977-),男,博士,E-mail:wxk111506@sohu.com。
更新日期/Last Update: 1900-01-01